46834-56-4

Basic information

• Product Name: (-)-4'-CHLOROTARTRANILIC ACID
• Synonyms: (-)-4'-CHLOROTARTRANILIC ACID;D-TACA;D-TARTARIC ACID MONO-P-CHLOROANILIDE;(S,S)-4'-Chloro-tartranilic acid;(2S,3S)-4-((4-Chlorophenyl)aMino)-2,3-dihydroxy-4-oxobutanoic acid
• CAS NO: 46834-56-4
• Molecular Formula: C₁₀H₁₀ClNO₅
• Molecular Weight: 259.64
• Mol File: 46834-56-4.mol
• Article Data: 3

Chemical Properties

• Melting Point: 193-195°C (dec.)
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (-)-4'-CHLOROTARTRANILIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (-)-4'-CHLOROTARTRANILIC ACID(46834-56-4)
• EPA Substance Registry System: (-)-4'-CHLOROTARTRANILIC ACID(46834-56-4)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 46834-56-4(Hazardous Substances Data)

Usage

General Description

(-)-4'-Chlorotartranilic acid is a chemical compound that belongs to the class of organic compounds known as 4-alkoxybenzoic acids. It is a white solid that is slightly soluble in water and commonly used as a building block in the chemical synthesis of various pharmaceuticals, dyes, and pigments. Its chemical structure consists of a benzene ring with a carboxylic acid group and a chlorine atom attached to the ortho position. (-)-4'-CHLOROTARTRANILIC ACID is primarily used as an intermediate in the manufacture of biologically active molecules and can also be used as a ligand in coordination chemistry. It is important to handle this compound with caution and follow proper safety protocols due to its potential hazards and risks associated with its handling and use.

Upstream product

• 70728-23-3 (3S,4S)-2,5-dioxotetrahydrofuran-3,4-diyl diacetate 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 943964-34-9 (R)-(+)-5-(4-amino-3-methylphenyl)-8-methyl-8,9-dihydro-7H-1,3-dioxolo[4,5-h][2,3]benzodiazepine salt with L-tartaric acid semi-4-chloroanilide 

Relevant articles and documents

Preparation method of (S)-1-tert-butyloxycarbonyl-3-hydroxypiperidine

The invention discloses a preparation method of (S)-1-tert-butyloxycarbonyl-3-hydroxypiperidine, and relates to the technical field of biological pharmacy. The preparation method comprises the following steps: 1, preparing 3-hydroxypyridine (2) as a raw material; 2, preparing racemic 3-hydroxypiperidine (3) from 3-hydroxypyridine (2); 3, preparing a derivative (2S, 3S)-N-(4-chlorphenyl)-2, 3-dihydroxy succinamic acid (4) from racemic 3-hydroxypiperidine (3) and D-tartaric acid; 4, carrying out resolution reaction on the derivative (2S, 3S)-N-(4-chlorphenyl)-2, 3-dihydroxy succinamic acid (4) prepared from D-tartaric acid to obtain a (S)-hydroxypiperidine salt (5); and 5, subjecting an obtained mixture to extraction, concentration and crystallization, to prepare a (S)-1-tert-butyloxycarbonyl-3-hydroxypiperidine salt (5). The preparation process has the advantages that the synthesis steps are reduced, the yield is increased, an adopted chiral resolving agent can be recycled, and the preparation process is suitable for industrial production.

Synthesis and pharmacological activity of stereoisomers of 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester

1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester 1, a highly potent calcium antagonist, was separated into stereo- and optical isomers to investigate the differences of antihypertensive activities between them. Fractional crystallization of the hydrochlorides of 1 gave α- and β-diasterioisomers. The α-isomer (benidipine hydrochloride, KW-3049) showed very strong hypotensive effect, but little activity was observed in the β-isomer. From optically resolved 1,4-dihydro-5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridi necarboxylic acids 2, and 1-benzyl-3-piperidinols 3, four optical isomers of 1 were synthesized, and their absolute configurations were deduced. The hypotensive activity of (+)-α, namely (S)-(S)-1, was 30 to 100 times stronger than that of (-)-α in intravenously administered spontaneously hypertensive rats.